Breaking News Instant updates and real-time market news.

CMTL

Comtech

$12.66

0.03 (0.24%)

, GPS

Gap

$22.78

0.25 (1.11%)

17:51
10/06/16
10/06
17:51
10/06/16
17:51

On The Fly: After Hours Movers

UP AFTER EARNINGS: Comtech (CMTL), up 2.7%. ALSO HIGHER: Gap (GPS), up 6% after it reported September same-store sales figures... CIT Group (CIT), up 5.8% after it agreed to sell CIT Commercial Air to Avolon Holdings for $10B... Dynavax (DVAX), up 4.5% after Point72 Asset reported a 5.9% passive stake in the company. DOWN AFTER EARNINGS: Mistras (MG), down 6.1%... Ruby Tuesday (RT), down 5.2%... Helen of Troy (HELE), down 2.7%. ALSO LOWER: Honeywell (HON), down 4% after it revised its guidance views for the third and fourth quarters... AxoGen (AXGN), down 2.2% after it announced a common stock offering.

CMTL

Comtech

$12.66

0.03 (0.24%)

GPS

Gap

$22.78

0.25 (1.11%)

CIT

CIT Group

$36.40

0.14 (0.39%)

DVAX

Dynavax

$10.77

-0.41 (-3.67%)

MG

Mistras

$23.33

0.08 (0.34%)

RT

Ruby Tuesday

$2.51

0.04 (1.62%)

HELE

Helen of Troy

$86.87

0.37 (0.43%)

HON

Honeywell

$115.61

0.35 (0.30%)

AXGN

AxoGen

$8.24

-0.21 (-2.49%)

  • 06

    Oct

  • 06

    Oct

  • 07

    Oct

  • 07

    Oct

  • 12

    Oct

  • 21

    Oct

  • 16

    Nov

  • 15

    Dec

  • 07

    Oct

CMTL Comtech
$12.66

0.03 (0.24%)

08/24/16
SBSH
08/24/16
INITIATION
SBSH
Neutral
Comtech initiated with a Neutral at Citi
Citi analyst Stanley Kovler started coverage on Comtech with a Neutral rating and $13 price target, saying that the company faces meaningful headwinds in certain mature markets and a challenging overall Army budget but that its high dividend yield makes near-term downside limited.
07/22/16
LTCO
07/22/16
INITIATION
Target $19
LTCO
Buy
Comtech initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson started Comtech Telecommunications with a Buy rating and $19 price target.
07/06/16
NORL
07/06/16
INITIATION
Target $20
NORL
Outperform
Comtech initiated with an Outperform at Northland
Target $20.
06/20/16
BMOC
06/20/16
INITIATION
Target $19
BMOC
Outperform
Comtech initiated with an Outperform at BMO Capital
BMO Capital analyst Timothy Long initiated Comtech with an Outperform and price target of $19.
GPS Gap
$22.78

0.25 (1.11%)

08/19/16
JEFF
08/19/16
NO CHANGE
Target $30
JEFF
Buy
Gap price target raised to $30 from $26 at Jefferies
Jefferies analyst Randal Konik raised his price target for Gap to $30 saying the company's Q2 results "point to trends moving in the right direction." The analyst views the shares as attractive at current levels and reiterates a Buy rating on the name.
07/25/16
STPT
07/25/16
DOWNGRADE
STPT
Hold
Gap downgraded to Hold from Buy at Standpoint Research
08/19/16
MSCO
08/19/16
NO CHANGE
Target $21
MSCO
Underweight
Gap valuation stretched adn upside limited, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said Gap's valuation appears stretched and upside is limited. The analyst said even the most bullish expectations for $2.25-$2.30 in 2017 implies zero earnings growth since 2012, with less scope for cuts in marketing expense, wage inflation, and other SG&A inflation. Greenberger has an Underweight rating on Gap and a $21 price target on shares.
08/09/16
MZHO
08/09/16
UPGRADE
MZHO
Neutral
Gap upgraded to Neutral from Underperform at Mizuho
CIT CIT Group
$36.40

0.14 (0.39%)

04/29/16
BOFA
04/29/16
DOWNGRADE
BOFA
Follow-up: CIT Group downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded CIT Group to Underperform from Buy. The firm's analyst said the restructuring to a complex franchise from a simplified bank may be extended until 2018 or longer, due to additional restructuring, a revised strategy, and a management overhaul. BofA/Merrill sees limited earnings visibility and believes sentiment will remain poor until the commercial air exit is complete and execution on the strategic plan shows progress.
03/28/16
03/28/16
DOWNGRADE

Neutral
CIT Group downgraded to Neutral from Buy at Sterne Agee CRT
03/28/16
03/28/16
DOWNGRADE

Neutral
CIT Group downgraded at Sterne Agee CRT
As noted earlier, Sterne Agee CRT downgraded CIT Group to Neutral from Buy. As reasons for the downgrade, the firm cited several factors, including the company's admission that it will need more time than expected to achieve its targeted profitability. The firm also cited the higher than expected cost of the spin off of the compsny's air leasing business and its belief that the company's ROE is below that of its peers. Target $37.
04/29/16
BOFA
04/29/16
DOWNGRADE
BOFA
Underperform
CIT Group downgraded to Underperform from Buy at BofA/Merrill
DVAX Dynavax
$10.77

-0.41 (-3.67%)

09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
04/27/16
COWN
04/27/16
NO CHANGE
Target $60
COWN
Outperform
Dynavax PDUFA extension will not impact approval chances, says Cowen
Cowen analyst Phil Nadeau does not beleive Dynavax's Heplisav PDUFA extension by 3 months will impact chances of approval. The analyst suspects that the PDUFA change has more to do with FDA managing its workload than any reflection on the substance of the BLA, since both the FDA and Dynavax had agreed upon the original format of the BLA resubmission. Nadeau continues to rate Dynavax an Outperform and top small cap pick with a $60 price target on shares.
04/27/16
RBCM
04/27/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded to Sector Perform from Outperform at RBC Capital
MG Mistras
$23.33

0.08 (0.34%)

12/16/15
SIDC
12/16/15
DOWNGRADE
Target $22
SIDC
Neutral
Mistras downgraded to Neutral from Buy at Sidoti
Sidoti downgraded Mistras to Neutral and lowered its price target to $22 from $25 on shares.
12/16/15
12/16/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Capital Agency (AGNC) downgraded to Underweight from Equal Weight at Morgan Stanley... Anglo American (AAUKY) downgraded to Hold from Buy at Deutsche Bank... BOK Financial (BOKF) downgraded to Neutral from Overweight at Piper Jaffray... BT Group (BT) downgraded to Sell from Hold at Deutsche Bank... Cabela's (CAB) downgraded to Neutral from Buy at SunTrust... Carlyle Group (CG) downgraded to Hold from Buy at Deutsche Bank... Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank... Dover (DOV) downgraded to Market Perform from Outperform at William Blair... General Dynamics (GD) downgraded to Neutral from Overweight at JPMorgan... GrubHub (GRUB) downgraded to Market Perform from Outperform at Northland... Heartland Payment (HPY) downgraded to Neutral from Buy at SunTrust... Jarden (JAH) downgraded to Sector Perform from Top Pick at RBC Capital... Kennametal (KMT) downgraded to Underperform from Neutral at Longbow... Liberty Property (LPT) downgraded on results at Stifel... Lonmin (LNMIY) downgraded to Sell from Buy at Deutsche Bank... Mid-America Apartment (MAA) downgraded to Sector Weight from Overweight at KeyBanc... Mistras (MG) downgraded to Neutral from Buy at Sidoti... Nabors Industries (NBR) downgraded on results at Argus... Nationstar (NSM) downgraded to Underweight from Equal Weight at Morgan Stanley... Norsk Hydro (NHYDY) downgraded to Hold from Buy at Deutsche Bank... Orexigen (OREX) downgraded to Hold from Buy at WallachBeth... RPX Corp. (RPXC) downgraded to Neutral at Baird... Swift Energy (SFY) downgraded to Neutral from Buy at Ladenburg... Terex (TEX) downgraded to Hold from Buy at Deutsche Bank... TransDigm (TDG) downgraded to Neutral from Overweight at JPMorgan... Zurich Insurance (ZURVY) downgraded to Hold from Buy at Jefferies.
08/12/16
BARD
08/12/16
UPGRADE
Target $28
BARD
Outperform
Mistras upgraded to Outperform from Neutral at Baird
Baird analyst Andrew Wittmann upgraded Mistras to Outperform and raised its price target to $28 from $27 following the selloff on earnings/guidance and the founder/CEO stock sale of 1M shares. The analyst said the CEO sold shars back to the company and notes he has had health issues and represents 8% of his position. Wittmann believes the company's comprehensive initiatives to improve operational inefficiencies will improve franchise value and that improving margins and cash flows are ahead.
04/07/16
KEYB
04/07/16
DOWNGRADE
KEYB
Sector Weight
Mistras downgraded to Sector Weight from Overweight at KeyBanc
RT Ruby Tuesday
$2.51

0.04 (1.62%)

12/08/15
TIGR
12/08/15
DOWNGRADE
TIGR
Underperform
Ruby Tuesday downgraded to Underperform from Neutral at Tigress Financial
07/08/16
ADAM
07/08/16
NO CHANGE
ADAM
Casual dining checks point to significant deceleration in June, says Canaccord
Canaccord analyst Lynne Collier said the firm's checks indicate a material decline in sales and traffic trends in casual dining restaurants was seen in June. Among the reasons for the slowdown, Collier points to the reversal in gasoline prices, consumers eating at home and the uncertain political environment. The analyst projects same-store sales for the casual dining segment will decline 2%-2.5% in June. Publicly traded companies that own casual dining brands include Darden (DRI), Ruby Tuesday (RT), Bloomin' Brands (BLMN), DineEquity (DIN), Denny's (DENN), Brinker (EAT) and Buffalo Wild Wings (BWLD).
02/18/16
SIDC
02/18/16
INITIATION
Target $6
SIDC
Neutral
Ruby Tuesday initiated with a Neutral at Sidoti
Target $6.
HELE Helen of Troy
$86.87

0.37 (0.43%)

03/07/16
03/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AveXis (AVXS) initiated with a Buy at Goldman and Jefferies. Goldman analyst Salveen Richter calls the company's clinical proof-of-concept for lead gene therapy AVXS-101 in spinal muscular atrophy Type I "impressive." 2. Proteostasis (PTI) initiated with a Buy at H.C. Wainwright and an Outperform at Baird, Leerink and RBC Capital. 3. Blue bird (BLBD) initiated with a Buy at Craig-Hallum by analyst Eric Stine, who cited discounted valuation and free cash flow generation. 4. Enbridge (ENB) initiated with a Buy at Canaccord following the company's $2.3B equity financing. The firm expects the financing removes any near-term funding risks. 5. Helen of Troy (HELE) initiated with a Buy at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/16
JEFF
03/07/16
INITIATION
Target $114
JEFF
Buy
Helen of Troy initiated with a Buy at Jefferies
Jefferies analyst Trevor Young started Helen of Troy with a Buy rating and $114 price target.
08/19/16
SIDC
08/19/16
UPGRADE
SIDC
Buy
Helen of Troy upgraded to Buy from Neutral at Sidoti
Sidoti analyst Frank Camma upgraded Helen of Troy to Buy based on valuation and strong consumer brands and maintained its $112 price target.
12/30/15
PIPR
12/30/15
NO CHANGE
Target $100
PIPR
Overweight
Helen of Troy shares look range-bound near-term, says Piper Jaffray
Piper Jaffray analyst Stephanie Wissink believes Helen of Troy shares are likely to be range-bound in the near-term with the 2015-2016 flu season tracking below last year. Management's guidance assumes an average flu season, the analyst points out. She still sees potential share upside though 2016, however, and keeps an Overweight rating on the name.
HON Honeywell
$115.61

0.35 (0.30%)

10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
09/09/16
JPMS
09/09/16
NO CHANGE
Target $132
JPMS
Overweight
JPMorgan makes Honeywell a top pick after recent correction
The recent correction in shares of Honeywell is understandable given the company's mixed fundamentals in the first half of 2016 and uncertainty around CEO succession, JPMorgan analyst C. Stephen Tusa tells investors in a research note. The current discount to peers at 10% is now too wide, Tusa argues. He says Honeywell is now a top pick in the Electrical Equipment & Multi-Industry space. The analyst keeps an Overweight rating on the shares with a $132 price target.
10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Outperform
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
08/22/16
MONN
08/22/16
NO CHANGE
MONN
W.R. Grace cold be a fit for Honeywell, says Monness Crespi
Monness Crespi said W.R. Grace (GRA) could be a target of Honeywell (HON) after its UOP division ended its alliance with Albemarle (ALB).
AXGN AxoGen
$8.24

-0.21 (-2.49%)

08/04/16
JMPS
08/04/16
NO CHANGE
JMPS
AxoGen price target raised to $13 from $8 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on AxoGen after the company reported stronger than expected results. The analyst continues to believe that the company's product "can become a new standard of care in nerve repair." He keeps an Outperform rating on the shares.
08/04/16
JMPS
08/04/16
NO CHANGE
JMPS
AxoGen price target raised to $13 from $8 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on AxoGen after the company reported stronger than expected results. The analyst continues to believe that the company's product "can become a new standard of care in nerve repair." He keeps an Outperform rating on the shares.
11/06/15
JMPS
11/06/15
NO CHANGE
JMPS
AxoGen price target raised to $8 from $5.50 at JMP Securities
JMP Securities raised its price target on AxoGen as the firm thinks the company reported very strong Q3 results. The firm continues to believe that the company's Avance product can become the new standard of care in nerve repair. It keeps an Outperform rating.

TODAY'S FREE FLY STORIES

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.